Publications by authors named "E Al-Abadi"
Objectives: We aimed to study the disease course, outcomes, and predictors of outcome in pediatric-onset anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affecting the kidneys.
Methods: Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or ANCA positive pauci-immune glomerulonephritis, were ≤ 18 years at diagnosis, had renal disease defined by biopsy or dialysis dependence, and had clinical data at diagnosis and either 12- or 24-months. Ambispective data from the ARChiVE/PedVas Registry was used.
Article Synopsis
- The study compares the effectiveness and toxicity of two treatments, rituximab (RTX) and cyclophosphamide (CYC), for pediatric patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
- It analyzes data from 104 patients and finds no significant difference in remission rates or severe adverse events between the two treatment groups.
- Limitations of the study include the lack of standardized treatment protocols and the retrospective nature of the analysis.
Contributors to Organ Damage in Childhood Lupus: Corticosteroid Use and Disease Activity.
Rheumatology (Oxford)
October 2024
Background: Awareness of paediatric-specific predictors of damage in Childhood-lupus is needed to inform mitigation measures.
Objectives: To ascertain how clinical and demographic variables correlate with damage accrual and identify predictors of damage.
Methods: Analysis included UK JSLE Cohort Study participants.
Article Synopsis
- The study evaluates the safety, tolerability, and effectiveness of tofacitinib in children and adolescents with juvenile idiopathic arthritis (JIA) in a long-term extension (LTE) study.
- Out of 225 patients treated with tofacitinib, a high percentage experienced adverse events (AEs), although serious AEs were relatively low, with a focus on infection rates and disease activity.
- Results showed significant improvement in disease activity scores over time, with a notable increase in patients achieving inactive disease status after 48 months of treatment.
Objective: To derive childhood-onset SLE (cSLE) specific remission definitions for future treat-to-target (T2T) trials, observational studies, and clinical practice.
Methods: The cSLE International T2T Task Force conducted Delphi surveys exploring paediatric perspectives on adult-onset SLE remission targets. A modified nominal group technique was used to discuss, refine, and agree on the cSLE remission target criteria.